Biodexa Pharmaceuticals (BDRX) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing treatments for diseases with unmet medical needs, including familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare/orphan brain cancers.

• Lead assets include eRapa (rapamycin) for FAP and NMIBC, tolimidone for T1D, and MTX110 for rare brain cancers, with eRapa and tolimidone as current priorities.

• Business model centers on advancing clinical assets to proof-of-concept before seeking partners for late-stage development and commercialization.

• Proprietary drug delivery technologies (Q-Sphera, MidaSolve, MidaCore) are no longer a key priority.

Financial performance and metrics

• As of September 30, 2025, cash and cash equivalents totaled £2.79 million.

• Unaudited financial data as of September 30, 2025, with full annual results to be included in the 2025 Annual Report.

• Capitalization as of June 30, 2025: £4.04 million in cash and cash equivalents (actual), £15.81 million (as-adjusted post-offering); total equity £11.44 million (actual), £23.21 million (as-adjusted).

Use of proceeds and capital allocation

• Estimated net proceeds of $15.5 million from the offering, assuming all units are sold at $5.33 per unit.

• Proceeds intended to fund development programs, working capital, and general corporate purposes; pending use, funds will be invested in short-term, interest-bearing investments.

• Management has broad discretion in the application of net proceeds.